Skip to content
Sitravatinib
Sitravatinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase receptor UFO, vascular endothelial growth factor receptor 1, discoidin domain-containing receptor 2, tyrosine-protein kinase Mer, ephrin type-A receptor 3, mast/stem cell growth factor receptor Kit, vascular endothelial growth factor receptor 3, hepatocyte growth factor receptor, receptor-type tyrosine-protein kinase FLT3, vascular endothelial growth factor receptor 2, high affinity nerve growth factor receptor, and platelet-derived growth factor receptor alpha.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289—42——6
Liver neoplasmsD008113EFO_1001513C22.0121——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8041———5
Renal cell carcinomaD00229223———4
Breast neoplasmsD001943EFO_0003869C50—2———2
AdenocarcinomaD000230—1———1
Squamous cell neoplasmsD018307—1———1
Urologic neoplasmsD014571C64-C68—1———1
Kidney neoplasmsD007680EFO_0003865C6411———1
Biliary tract neoplasmsD001661C24.9—1———1
Triple negative breast neoplasmsD064726—1———1
LiposarcomaD008080—1———1
Show 8 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinoma of head and neckD0000771951————1
Squamous cell carcinomaD0022941————1
Hepatic insufficiencyD0485501————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSITRAVATINIB
INNsitravatinib
Description
Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)cc4F)c3s2)nc1
Identifiers
PDB—
CAS-ID1123837-84-2
RxCUI—
ChEMBL IDCHEMBL3989926
ChEBI ID—
PubChem CID25212148
DrugBankDB15036
UNII IDCWG62Q1VTB (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AXL
AXL
FLT1
FLT1
DDR2
DDR2
MERTK
MERTK
EPHA3
EPHA3
KIT
KIT
FLT4
FLT4
MET
MET
FLT3
FLT3
KDR
KDR
NTRK1
NTRK1
PDGFRA
PDGFRA
Organism
Homo sapiens
Gene name
AXL
Gene synonyms
UFO
NCBI Gene ID
558
Protein name
tyrosine-protein kinase receptor UFO
Protein synonyms
AXL oncogene, AXL transforming sequence/gene
Uniprot ID
P30530
Mouse ortholog
Axl (26362)
tyrosine-protein kinase receptor UFO (Q80YQ3)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 248 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
14 adverse events reported
View more details